Tin t&#x1EE9;c &amp; C&#x1EAD;p nh&#x1EAD;t

Pneumococcal polysaccharide vaccine shields older patients from adverse CV events

20 Aug 2020 bởi

The 23-valent pneumococcal polysaccharide vaccine (PPSV23), used to protect against 23 types of bacteria that cause pneumococcal disease, appears to have wider benefits—that is, reduce the risks of adverse cardiovascular (CV) events and mortality especially in older adults, a study has found.

Pneumococcal polysaccharide vaccine shields older patients from adverse CV events

PPI use may negatively influence COVID-19 outcomes

The use of proton pump inhibitors (PPIs) confers no risk increase for contracting SARS-CoV-2 infection, although PPI users with COVID-19 are likely to have severe outcomes, a study has found.

PPI use may negatively influence COVID-19 outcomes

Fidget spinner-based UTI testing device yields results in less than an hour

A novel hand-powered spinning device, which employs the principles of centrifugal force and a fidget spinner toy, can perform on-site detection of urinary tract infection (UTI) in about 50 minutes and may prove useful in low-resource settings, as reported in a study.

Fidget spinner-based UTI testing device yields results in less than an hour

Dolutegravir remains noninferior to low-dose efavirenz for HIV-1 after 96 weeks

A dolutegravir-based regimen continued to show noninferiority to a low-dose efavirenz-based regimen after 96 weeks for the initial treatment of HIV-1 infection, according to the updated results of the NAMSAL* trial presented at AIDS 2020.

Dolutegravir remains noninferior to low-dose efavirenz for HIV-1 after 96 weeks

Smell, taste dysfunction among COVID-19 patients unrelated to viral load

Although olfactory and gustatory dysfunctions are common among patients with the coronavirus disease 2019 (COVID-19), they do not exhibit a clear connection to viral load, according to a recent study.

Smell, taste dysfunction among COVID-19 patients unrelated to viral load

A new molecule has been approved in Europe for the treatment of drug resistant TB.

A new compound has been granted conditional marketing authorization by the European Commission (EC) for treating highly drug-resistant forms of pulmonary tuberculosis (TB).

A new molecule has been approved in Europe for the treatment of drug resistant TB.